{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:59:49Z","timestamp":1786636789702,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:p>\n                    Bipolar disorder (BD) is a chronic mental health condition characterized by alternating manic and depressive episodes that significantly impact mood and cognitive function. Recent research has linked BD to neuroinflammation. Despite the availability of antipsychotics and mood stabilizers as standard treatments, their efficacy and side effects can vary, underscoring the need for more effective therapeutic strategies. This study aims to evaluate the combined effects of olanzapine and sodium valproate on clinical symptoms and inflammatory markers in patients with BD. A total of 80 BD patients from the Fifth People\u2019s Hospital of Jiujiang, treated between April 2022 and April 2024, were enrolled in the study. They were divided into 2 groups: the control group, which received olanzapine monotherapy, and the observation group, which received a combination of olanzapine and sodium valproate. After 8 weeks of treatment, clinical efficacy was assessed using the Bech-Rafaelsen Mania scale and the Hamilton depression scale. Serum inflammatory markers, including interleukin-1, interleukin-10, and tumor necrosis factor-alpha, were measured along with neuroendocrine function indicators (thyroid hormone, cortisol, thyroid-stimulating hormone, and adrenocorticotropic hormone). Cognitive function was evaluated using computerized assessments, and adverse events were monitored and recorded. The observation group exhibited significantly lower Bech-Rafaelsen Mania scale and Hamilton depression scale scores, as well as reduced interleukin-1 and tumor necrosis factor-alpha levels compared to the control group. Both groups showed decreased levels of serum thyroid hormone, cortisol, and adrenocorticotropic hormone, along with increased thyroid-stimulating hormone levels after treatment, with more pronounced changes observed in the observation group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01). Additionally, cognitive function scores were significantly higher in the observation group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05), and the incidence of adverse events was lower (15.00% vs 22.50%, \u03c7\u00b2\u2005=\u20050.38,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.01). The combination of olanzapine and sodium valproate leads to significant improvements in clinical symptoms, reduces inflammatory markers, enhances cognitive function, and demonstrates greater safety compared to olanzapine monotherapy. This combination therapy offers a promising treatment approach for managing BD.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042803","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:00:34Z","timestamp":1751295634000},"page":"e42803","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Effects of olanzapine combined with sodium valproate on symptoms, inflammatory markers, and cognitive function in patients with bipolar disorder"],"prefix":"10.1097","volume":"104","author":[{"given":"Xiao","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Psychological Assessment Room, Jiujiang Fifth People\u2019s Hospital, Jiujiang, Jiangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Functional Inspection Room, Jiujiang No. 1 People\u2019s Hospital, Jiujiang, Jiangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, The Fifth People\u2019s Hospital of Jiujiang City, Jiujiang, Jiangxi Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qigui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People\u2019s Hospital, Jiujiang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3859-6205","authenticated-orcid":false,"given":"Guanhua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Jiujiang City Key Laboratory of Cell Therapy, Jiujiang No. 1 People\u2019s Hospital, Jiujiang, Jiangxi Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hbm.25098","article-title":"What we learn about bipolar disorder from large-scale neuroimaging: findings and future directions from the ENIGMA bipolar disorder working group.","volume":"43","author":"Ching","year":"2022","journal-title":"Hum Brain Mapp"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"104764","DOI":"10.1016\/j.neubiorev.2022.104764","article-title":"Visual electrophysiology and neuropsychology in bipolar disorders: a review on current state and perspectives.","volume":"140","author":"Tursini","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"R3-20260813","doi-asserted-by":"crossref","first-page":"e8508","DOI":"10.1136\/bmj.e8508","article-title":"Bipolar disorder.","volume":"345","author":"Anderson","year":"2012","journal-title":"BMJ"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jad.2018.02.085","article-title":"Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants.","volume":"234","author":"Fornaro","year":"2018","journal-title":"J Affect Disord"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.2174\/1381612827666210603143353","article-title":"Suicide and genetic biomarkers: toward personalized tailored-treatment with lithium and clozapine.","volume":"27","author":"De Berardis","year":"2021","journal-title":"Curr Pharm Des"},{"key":"R6-20260813","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4088\/JCP.v64n0209","article-title":"Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder.","volume":"64","author":"Hirschfeld","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R7-20260813","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41537-021-00192-x","article-title":"Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics.","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"R9-20260813","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"R11-20260813","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"R12-20260813","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S0033291714001305","article-title":"A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.","volume":"45","author":"Yildiz","year":"2015","journal-title":"Psychol Med"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/schbul\/sbq042","article-title":"Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.","volume":"38","author":"Rummel-Kluge","year":"2012","journal-title":"Schizophr Bull"},{"key":"R14-20260813","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1176\/appi.focus.10.2.194","article-title":"The 2009 Schizophrenia PORT psychopharmacological treatment recommendations and summary statements.","volume":"10","author":"Buchanan","year":"2012","journal-title":"Focus"},{"key":"R15-20260813","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","article-title":"Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.","volume":"71","author":"Correll","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2017.16080919","article-title":"Psychopharmacological treatment in the RAISE-ETP study: outcomes of a manual and computer decision support system based intervention.","volume":"175","author":"Robinson","year":"2018","journal-title":"Am J Psychiatry"},{"key":"R17-20260813","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/schbul\/sbaa191","article-title":"Does switching antipsychotics ameliorate weight gain in patients with severe mental illness? A systematic review and meta-analysis.","volume":"47","author":"Siskind","year":"2021","journal-title":"Schizophr Bull"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10067-012-2150-x","article-title":"Valproate-induced hyperammonaemia superimposed upon severe neuropsychiatric lupus: a case report and review of the literature.","volume":"32","author":"Chan","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R19-20260813","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1600-0447.1979.tb04484.x","article-title":"The Bech-Rafaelsen mania scale and the hamilton depression scale.","volume":"59","author":"Bech","year":"1979","journal-title":"Acta Psychiatr Scand"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the hamilton depression rating scale.","volume":"150","author":"Zimmerman","year":"2013","journal-title":"J Affect Disord"},{"key":"R21-20260813","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jad.2011.10.014","article-title":"A systematic review of instruments to measure depressive symptoms in patients with schizophrenia.","volume":"140","author":"Lako","year":"2012","journal-title":"J Affect Disord"},{"key":"R22-20260813","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bbr.2008.08.026","article-title":"The effects of stressful stimuli and hypothalamic-pituitary-adrenal axis activation are reversed by the melanin-concentrating hormone 1 receptor antagonist SNAP 94847 in rodents.","volume":"197","author":"Smith","year":"2009","journal-title":"Behav Brain Res"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/2327-6924.12275","article-title":"Diagnosis and treatment of patients with bipolar disorder: a review for advanced practice nurses.","volume":"27","author":"McCormick","year":"2015","journal-title":"J Am Assoc Nurse Pract"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and International society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"R25-20260813","first-page":"PCC.10r01097","article-title":"The clinical management of bipolar disorder: a review of evidence-based guidelines.","volume":"13","author":"Connolly","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"key":"R26-20260813","first-page":"CD006282","article-title":"Drug treatment for spinal muscular atrophy types II and III.","volume":"1","author":"Wadman","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R27-20260813","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/pr.111.005512","article-title":"Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.","volume":"65","author":"Chiu","year":"2013","journal-title":"Pharmacol Rev"},{"key":"R28-20260813","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"key":"R29-20260813","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40261-019-00860-y","article-title":"Combination of olanzapine and samidorphan has no clinically significant effect on the pharmacokinetics of lithium or valproate.","volume":"40","author":"Sun","year":"2020","journal-title":"Clin Drug Investig"},{"key":"R30-20260813","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jad.2012.02.016","article-title":"Towards a multifactorial approach for prediction of bipolar disorder in at risk populations.","volume":"140","author":"Brietzke","year":"2012","journal-title":"J Affect Disord"},{"key":"R31-20260813","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pbb.2018.12.006","article-title":"Revisiting inflammation in bipolar disorder.","volume":"177","author":"Fries","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"R32-20260813","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/02537176231154270","article-title":"IL-10 dysregulation in bipolar disorder: potential mechanisms and treatment implications.","volume":"45","author":"Mopuru","year":"2023","journal-title":"Indian J Psychol Med"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/B978-0-444-52002-9.00015-2","article-title":"Bipolar disorder.","volume":"106","author":"Smith","year":"2012","journal-title":"Handb Clin Neurol"},{"key":"R34-20260813","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jad.2022.05.017","article-title":"Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.","volume":"311","author":"Roosen","year":"2022","journal-title":"J Affect Disord"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042803","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:01:05Z","timestamp":1786633265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":34,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042803","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}